VeCollal, developed by Corpowell, has confirmed an investment by Seventure Partners (via Health For Life Capital) at the Fi Europe exhibition in Paris.
The company simultaneously announced a clinical breakthrough with a 20% reduction in visible cellulite, opening up the market to cosmetic companies.
With these milestones, VeCollal positions itself as the leading, science-backed player in the rapidly growing nutraceuticals market.
VeCollal is presenting its complete portfolio at Fi Europe, featuring Type I (skin, hair, bones) and Type II (cartilage, joints) collagen alternatives — both supported by robust clinical studies and patent-pending, sustainable technology.
VeCollal is the world's first clinically proven, plant-based biomimetic, mimicking the natural amino acid profile of human collagen one-to-one.
This results in a superior, bio-identical foundation, which distinguishes VeCollal from incomplete animal collagen and simple 'boosters' on the market.
The core of VeCollal’s innovation lies in its efficiency and effectiveness.
Where animal collagen often requires 10-20 grams/day, VeCollal Type I delivers visible results with just 5 grams per day during an eight-week period, including a 32.9% reduction in wrinkle depth.
Tony Van Campen, CEO and founder of Corpowell: "As a former athlete, I know the importance of the right building blocks for the body."
"Throughout my career in the sector, I noticed we blindly accepted animal collagen, despite it being an incomplete protein."
"We decided to raise the bar: VeCollal is the result of our passion to create a perfect, biomimetic, 100% plant-based alternative that is better."
VeCollal / Corpowell secures investment from Seventure for global expansion
Corpowell, spearheaded by VeCollal, is committed to exponential growth following a successful investment round led by Seventure Partners, a European leader in Venture Capital, Growth & Private Equity.
VeCollal has already secured robust early momentum with strategic partnerships in the United States and Europe, including co-branding projects with prominent brands such as Feel, Ringana, Aroma-Zone, Solaray and Life Extension.
The capital injection validates the biomimetic technology and accelerates global rollout.
Isabelle de Cremoux, CEO of Seventure Partners: "We believe in the transition to sustainable, AI-driven Health Tech, Nutrition and Food solutions."
"The VeCollal technology is not only substantially more CO2-efficient than animal collagen, but the company also has a scalable, B2B model with strong traction in the United States, Asia and Europe."
"Our investment is intended to accelerate the global rollout and establish VeCollal as the leading brand in biomimetic high-value, protein alternative ingredients."
Corpowell is targeting a 10× revenue growth by 2028 to become the dominant European player.
Ethics, ecology and efficiency: 83% less CO₂ thanks to fermentation
VeCollal eliminates the ethical and ecological challenges of animal collagen.
The Life Cycle Assessment (LCA) of VeCollal confirms that its fermentation-based process has an 83% lower CO₂ emission compared to traditional animal collagen.
Thanks to this proven sustainability and the absence of ethical concerns regarding animal welfare, VeCollal demonstrably helps brands achieve their ESG (Environmental, Social, Governance) objectives and minimise supply chain risks.
Furthermore, the use of fermented plant-based amino acids guarantees a halal/kosher-suitable, allergen-free, non-GMO and traceable ingredient.
This fully meets Clean Label requirements, making VeCollal the perfect partner for transparent and pure products.
Tony Van Campen, CEO and founder of Corpowell: "For me, VeCollal is about removing the choice between ethics and results."
"Consumers want sustainability and proven effectiveness. By replicating the amino acid structure of human collagen and activating its production in the body, we offer an intelligent alternative that genuinely makes a difference."
"That is the definition of Collagen 2.0 for us."